PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-123.39
Negative P/E while Drug Manufacturers - Specialty & Generic median is 7.38. Seth Klarman would scrutinize path to profitability versus peers.
29715.69
P/S exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 12.35. Jim Chanos would check for potential multiple compression risks.
111.61
P/B exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.15. Jim Chanos would check for potential asset write-down risks.
-604.09
Negative FCF while Drug Manufacturers - Specialty & Generic median P/FCF is -3.48. Seth Klarman would investigate cash flow improvement potential.
-713.24
Negative operating cash flow while Drug Manufacturers - Specialty & Generic median P/OCF is 0.00. Seth Klarman would investigate operational improvement potential.
111.61
Fair value ratio exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.15. Jim Chanos would check for valuation bubble risks.
-0.20%
Negative earnings while Drug Manufacturers - Specialty & Generic median yield is 0.13%. Seth Klarman would investigate path to profitability.
-0.17%
Negative FCF while Drug Manufacturers - Specialty & Generic median yield is -0.02%. Seth Klarman would investigate cash flow improvement potential.